Download >> Download Clin cancer res instructions authors like vince
Read Online >> Read Online Clin cancer res instructions authors like vince
doi 10.1158 1078 0432
clinical cancer research
Looking Forward: An Update to the CCR Instructions for Authors. Jesse Potash and Clin Cancer Res July 15 2014 20 (14) 3629-3629; DOI:10.1158/1078-0432.CCR-14-1456 . A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma.
15 Apr 2013 Abstract. Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish
15 Oct 2004 Acknowledgments. The authors would like to thank G. Dittonno, M. Gianotti, and J. Rowand for processing patient samples. We also thank J. Note: Supplementary data for this article can be found at Clinical Cancer Research Online (clincancerres.aacrjournals.org). Requests for reprints: W. Jeffrey
Clin Cancer Res November 21 2017 DOI:10.1158/1078-0432.CCR-17-1766. Biology of Human Tumors | AUTHOR MANUSCRIPT. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy. Martin Puhr, Julia Hoefer, Andrea Eigentler, Christian Ploner,
Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer. Ann H. Rosendahl, Claire M. Perks, Li Zeng, Andrea Markkula, Maria Simonsson, Carsten Rose, Christian Ingvar, Jeff M.P. Holly and Helena Jernstrom. Clin Cancer Res April 15
After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond. Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party. Who decides whether my work will be accepted? - Peer-review policy; Want to
1 Sep 2011 Importantly, what defines acquired resistance is progression while receiving EGFR-TKI, irrespective of “line of therapy.” Rather, “TKI resistance” in EGFR-mutant lung cancer is a therapy-dependent clinical state, much like “castrate resistance” in prostate cancer (4). As in prostate cancer, one should ensure
19 Sep 2014 Clin Cancer Res. Author manuscript; available in PMC 2015 Nov 15. Published in final edited form as: Clin Cancer Res. 2014 Nov 15; 20(22): 5787–5795. . Once the optimal models were identified, clinical information for the validation samples were unblinded and the model predictions were evaluated.
1 Jan 2017 Ingrid A. Mayer, Vandana G. Abramson, Luigi Formisano, Justin M. Balko, Monica V. Estrada, Melinda E. Sanders, Dejan Juric, David Solit, Michael F. Berger, Helen H. Won, Yisheng Li, Lewis C. Cantley, Eric Winer and Carlos L. Arteaga. Clin Cancer Res January 1 2017 23 (1) 26-34;
15 Aug 2009 Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an .. Median OS was ?1 year, similar to the estimated survival noted in other trials of patients with metastatic non–small cell lung cancer.
http://svwiqhs.volshebniy.ru/viewtopic.php?id=172 http://umuuohx.bbon.ru/viewtopic.php?id=58 http://svwiqhs.volshebniy.ru/viewtopic.php?id=83 https://www.scoop.it/t/fkphbko/p/4089596722/2017/11/25/guide-clamp-silverline-resort http://svwiqhs.volshebniy.ru/viewtopic.php?id=148